Videos

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses what oncologists have learned from experience with supportive care that can be applied to adopting anticancer biosimilars.

Erich Mounce, chief operating officer, OneOncology, discusses the role that biosimilars will have in practices meeting Oncology Care Model (OCM) goals.

Brian Lehman, MBA, MHA, RPh, director, Medical Account Management and Strategic Alliances, Sandoz, discusses positive developments for biosimilars over the past year.

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses how biosimilars have impacted innovation in oncology.

Jeffrey Patton, MD, chief executive officer of Tennessee Oncology and president of physician services for OneOncology, discusses adoption of biosimilar trastuzumab, bevacizumab, and rituximab.

Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), discusses the challenges inherent in conducting large-scale comparative effectiveness research on biologics and biosimilars.

Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses the process to select the right biologic for a patient with inflammatory bowel disease (IBD).

Robin Shah, chief commercial officer of OneOncology, addresses the role that biosimilars have in community oncology.

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses the launch of the first rituximab biosimilar in the United States.

Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic, discusses how comfortable rheumatologists are with using biosimilars.

Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses financial toxicity in cancer care.

Robin Shah, chief commercial officer of OneOncology, addresses how practices can communicate the value of biosimilars to patients.

Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses how route of administration impacts patient adherence to inflammatory bowel disease (IBD) therapy.

Tracy L. Bahl, president and chief executive officer of OneOncology, discusses why his organization felt it was key to adopt biosimilars.

Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd, discusses the role that biosimilars have to play in reducing patients’ out-of-pocket costs in cancer care.

Terrill Jordan, chief executive officer of Regional Cancer Care Associates (RCCA), discusses how RCCA is handling biosimilar availability.

Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses the role biosimilars have to play in reducing patient costs.

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses the need for practice-wide education concerning biosimilars in cancer care.

Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc, addresses the role that biosimilars will have in alternative payment models in oncology.

Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses the role of therapeutic drug monitoring in treating patients with inflammatory bowel disease (IBD).

Alexandra Valenti, JD, partner at Goodwin, discusses whether drug makers are given pause by the possibility of regulatory scrutiny of patent settlements.

Scott Gottlieb, MD, former commissioner of the FDA, discusses how to improve the US biosimilars market.

Nicholas Robert, MD, medical director of data, evidence and insights at McKesson Life Sciences, discusses the FDA’s role in helping providers become comfortable with biosimilars.

Alexandra Valenti, JD, partner at Goodwin, discusses what drug makers should consider as the United States approaches a regulatory transition for insulins.

Scott Gottlieb, MD, former commissioner of the FDA, discusses whether Congress should make changes to the Biologics Price Competition and Innovation Act (BPCIA) if the opportunity arises.

Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses how biosimilars fit in the treatment paradigm for inflammatory bowel disease (IBD).

Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses whether value-based contracts have a role to play in biosimilar uptake.

Scott Gottlieb, MD, former commissioner of the FDA, discusses what might become of the Biologics Price Competition and Innovation Act (BPCIA) if the Affordable Care Act (ACA) is invalidated.

Nicholas Robert, MD, medical director of data, evidence and insights at McKesson Life Sciences, discusses how comfortable oncologists are with using biosimilars.